Amrou Sarraj, MD
Vascular Neurology · Houston, TXNPI 1518264514
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $135,784 of the $181,777 with a category attached, or 74.7%. Stryker accounts for 94.2% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $140,710 and has fallen 99.9% since, to $161 in 2025. Among vascular neurology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 167 payments — averaging $1088.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$171K
- AstraZeneca$6K
- Genentech, Inc.$4K
- Viz.ai, Inc.$695
- Abbott$130
- CSL Behring$47
- plus $140 from 5 others
Across 13 payments — averaging $142,083 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Stryker$1.8M
What the payments were for
- Consulting fees$135,78475%
- Travel & lodging$41,57323%
- Food & beverage$4,4202%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 136 | $171,297 |
| AstraZeneca(2 entities) | 11 | $5,788 |
| Genentech, Inc. | 2 | $3,680 |
| Viz.ai, Inc. | 7 | $695 |
| Abbott | 2 | $130 |
| CSL Behring | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $46 |
| UCB, Inc. | 2 | $37 |
| Argenx US, Inc. | 1 | $25 |
| Pfizer | 1 | $18 |
| Neurelis, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$181,777 in reported general payments places this provider in the 95th percentile of 76 vascular neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other vascular neurology in Houston
- John VolpiHouston$407K
- Sunil ShethHouston$54K
- Haris KamalHouston$21K
- Sean SavitzHouston$20K
- Louise McCulloughHouston$14K
- Michael NahhasHouston$10K
- Rajan GadhiaHouston$5K
- Mohammad El-GhanemHouston$5K
- Robert RegenhardtHouston$5K
- Joseph FriesHouston$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.